Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric sodium zirconium cyclosilicate study in hyperkalaemia
2018-001331-48Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hyperkalemia comparing Sodium zirconium cyclosilicate with Placebo maintenance (2 arms). Primary endpoint: 28-day maintenance phase primary endpoint. Status: unknown.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2018-001331-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001331-48.